Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript Summary
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript Summary
Non-GAAP operating margin increased approximately 2 percentage points sequentially to minus 6%.The following is a summary of the Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript:
以下是Fulgent Genetics, Inc. (FLGT) 2024年第三季度业绩会交易摘要：
Financial Performance:
财务表现:
Total Q3 revenue was $71.7 million, a decrease from $84.7 million in the third quarter of 2023.
GAAP gross margin was 37.3%, with a non-GAAP gross margin of 40%.
Non-GAAP operating margin increased approximately 2 percentage points sequentially to minus 6%.
Adjusted EBITDA income for Q3 was approximately $400,000, compared to an income of $18.1 million in Q3 2023.
Projected improvement in GAAP EPS loss from $1.95 to approximately $1.70 per share for the full year.
第三季度总营业收入为7170万美元，低于2023年第三季度的8470万美元。
根据GAAP，毛利率为37.3％，非GAAP毛利率为40％。
非GAAP营业利润率按季度增加约2个百分点，达到-6％。
第三季度调整后的EBITDA收入约为40万美元，较2023年第三季度的1810万美元有所增加。
预计全年GAAP每股亏损从1.95美元降至约1.70美元。
Business Progress:
业务进展：
Expanded carrier screening and hereditary cancer screening tests are in high demand.
Established a new $99 million contract over five years with VA hospitals for hereditary cancer and other germline tests.
Introduced KNOVA, a novel NIPT test, and received MoIDX approval for multiple hereditary cancer panels in the third quarter.
扩大的携带者筛查和遗传性癌症筛查测试需求很高。
与VA医院达成了一项新的价值9900万美元的合同，为遗传性癌症和其他生殖系列测试服务五年。
推出了KNOVA，一种新型NIPt测试，并在第三季度获得了MoIDX对多种遗传性癌症面板的批准。
Opportunities:
机会：
Continued growth in core business areas: precision diagnostics, anatomic pathology, and pharma services.
The ability to further compete for biopharma service projects due to a larger test portfolio, including new platforms like 10x Genomics and Akoya.
Expanded presence in digital pathology, with 80% of slides digitized, enhancing operational efficiency and potential for integrating AI technologies in the future.
在核心业务领域持续增长：精准诊断，解剖病理学和制药服务。
由于测试组合更大，包括10x genomics和Akoya等新平台，能够进一步竞争生物制药服务项目。
在数字病理学领域扩大影响力，80%的幻灯片完成数字化，提高运营效率并增加将来整合人工智能技术的潜力。
Risks:
风险：
Revenue from COVID-19 testing is now negligible, implying a pivot to more sustainable core business offerings.
A projected operating margin of approximately minus 12% for the year highlights operational risks tied to investments for growth.
COVID-19测试的营业收入现在可以忽略不计，这意味着向更可持续的核心业务业务转型。
预计全年营业利润率约为负12%，凸显了与为增长投资相关的运营风险。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的详情，请参阅投资人关系网站。本文仅供投资者参考，不作任何指引或建议。
译文内容由第三方软件翻译。